Nurix Therapeutics, Inc. NRIX

Company Overview

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule therapies that modulate protein degradation. The company operates within the biotechnology and pharmaceutical industries, with a particular emphasis on targeted protein modulation using the ubiquitin-proteasome system. Its core approach leverages E3 ligase biology to selectively degrade disease-causing proteins that are difficult to address with traditional inhibitors.

The company’s primary revenue drivers currently consist of collaboration and license agreements with large pharmaceutical partners, as it does not yet have approved commercial products. Nurix serves oncology and immunology markets, targeting cancer and inflammatory diseases. Its strategic advantage lies in its proprietary DELigase platform, which enables the discovery of both targeted protein degraders and E3 ligase modulators. Nurix was founded in 2009 and has evolved from a discovery-focused research company into a clinical-stage organization with multiple assets in human trials and high-profile industry partnerships.